Amanote Research
Register
Sign In
Daunorubicin Dose in AML Induction
Blood
- United States
doi 10.1182/blood-2015-04-643825
Full Text
Open PDF
Abstract
Available in
full text
Categories
Biochemistry
Immunology
Cell Biology
Hematology
Date
June 18, 2015
Authors
Unknown
Publisher
American Society of Hematology
Related search
A Phase 1 Study of Concomitant High-Dose Lenalidomide and 5-Azacitidine Induction in the Treatment of AML
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results
American Journal of Hematology
Hematology
Efficacy and Toxicity of Idarubicin Versus High-Dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Wild-Type P53-Mediated Induction of Ratmdr1bExpression by the Anticancer Drug Daunorubicin
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Dose Intensification of Daunorubicin and Cytarabine During Treatment of Adult Acute Lymphoblastic Leukemia
Cancer
Cancer Research
Oncology
Verapamil Restoration of Daunorubicin Responsiveness in Daunorubicin-Resistant Ehrlich Ascites Carcinoma
Journal of Clinical Investigation
Medicine
Daunorubicin in Acute Leukæmia
The Lancet
Medicine
Propofol Induction: Normalizing the Dose in Morbidly Obese Patients
Canadian Journal of Anaesthesia
Medicine
Anesthesiology
Pain Medicine
High-Dose Chemotherapy With Autologous PDSCT as Post-Remission Therapy for AML
Bone Marrow Transplantation
Transplantation
Hematology
